Clinical Trials Logo

Inflammatory Bowel Diseases clinical trials

View clinical trials related to Inflammatory Bowel Diseases.

Filter by:

NCT ID: NCT04952558 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Delayed Diagnostic Time& Inflammatory Bowel Diseased Patients

Start date: July 1, 2021
Phase:
Study type: Observational [Patient Registry]

Introduction The incidence of inflammatory bowel disease [IBD] is increasing worldwide. Both Crohn's disease [CD] and ulcerative colitis [UC] are therefore becoming an important public health issue[1] The IBD is characterized by chronic intestinal inflammation, which can cause bowel damage and intestinal complications primarily depending on the duration and severity of the inflammation[2] The diagnosis of inflammatory bowel diseases (IBD) is often established following considerable delay due to nonspecific and inconsistent symptoms. In previous western studies, the delayed diagnosis was associated with poor outcome in patients with Crohn's disease (CD).[2] Timely diagnosis is not only important for the patients themselves but has also become a relevant public health issue due to the rising incidence of IBD worldwide[3] Patients and methods Cross sectional observational study will be conducted among 700 patients of Egyptian inflammatory bowel diseased patients for different regions Aim of the study 1. Estimate time delay for diagnosis of Egyptian inflammatory bowel diseased patients 2. compare the delay time for diagnosis of Egyptian inflammatory bowel diseased patients globally

NCT ID: NCT04946448 Recruiting - Crohn Disease Clinical Trials

COmbinAtion Therapy of dieT With biologicalS for Crohn's Disease: the OATS Study

OATS
Start date: September 14, 2021
Phase: N/A
Study type: Interventional

This study is a randomised open label study, comparing the FIT diet with standard diet in patients with Crohn's disease treated with biologic therapy.

NCT ID: NCT04924686 Recruiting - Colorectal Cancer Clinical Trials

Changes of Muramyl Dipeptide in Intestinal and Extra-intestinal Diseases

Start date: May 10, 2020
Phase:
Study type: Observational

Nucleotide-binding oligomerization domain 2 (Nod2) signaling is critical for human health.To figure out the clinical relevance of NOD2 ligands, the investigators plan to evaluate the change of NOD2 ligands in inflammatory bowel diseases (IBD), CRC, atherosclerotic cardiovascular disease (ACVD), and type 2 diabetes mellitus (DM2 ).

NCT ID: NCT04923100 Recruiting - Ulcerative Colitis Clinical Trials

Therapeutic Effect of New Biologics in Crohn's Disease

Start date: June 10, 2021
Phase:
Study type: Observational

New types of biologics have brought advantages in therapy strategies for Crohn's disease. However, clinical data evaluating their efficacy and adverse in China is lacking. We aimed to evaluate the short-term and long-term therapeutic effect as well as drug adverse of Ustekinumab (UST) and Vedolizumab (VED). Besides, we aim to figure out the independent factors predicting the effectiveness of new biologics. Relations between drug exposure (trough concentration and antibody concentration) and therapeutic efficacy are study in-depth by this retrospective observational study.

NCT ID: NCT04921709 Recruiting - Clinical trials for Irritable Bowel Syndrome

Renal Involvement in Inflammatory Bowel Disease Patients

Start date: June 1, 2021
Phase:
Study type: Observational

To evaluate renal involvement in inflammatory bowel disease patients .

NCT ID: NCT04916067 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Stoma Closure and Reinforcement Trial ll

SCAR-ll
Start date: December 1, 2021
Phase: N/A
Study type: Interventional

Hernia formation at sites of ostomy closure is a common complication. The investigator believes that using evidence based hernia repair techniques as a preventive measure during closure of ostomies will reduce the incidence of hernia formation. In this trial, the investigator will pilot a novel technique of monofilament bioresorbable mesh reinforcement of the abdominal wall defects that remain after closure of an ileostomy to evaluate for safety and begin to evaluate the effectiveness compared to standard techniques.

NCT ID: NCT04912999 Recruiting - Ulcerative Colitis Clinical Trials

Inflammatory Bowel Diseases Remission Registry

Start date: August 1, 2019
Phase:
Study type: Observational [Patient Registry]

The inflammatory bowel diseases (IBDs), ulcerative colitis (UC) and Crohn's disease (CD), are characterized by lifelong relapsing-remitting gastrointestinal inflammation, with symptoms of abdominal pain, diarrhea, and rectal bleeding during active disease. Medical therapy reduces intestinal inflammation and ameliorates symptoms. Clinical remission is defined when symptoms are resolved. In these periods, patients are able to perform daily activities more freely and lead a normal lifestyle. Biochemical remission (normalization of CRP and fecal Calprotectin) and endoscopic remission (no visual signs of inflammation of the mucosa in endoscopy) are the goals of IBD treatment. Unfortunately, 30-40% of patients will relapse during 6 months from achieving remission. Risk factors for disease exacerbation are still unknown, and no guidelines exist as to the prevention of relapse and maintenance of remission in IBD patients. In addition to the above, sleep disturbances and disturbances in the circadian rhythm can be a potential cause of flare-up. Sleep disorders cause changes in immune function, which later affect the course of the disease in IBD. This back affects the sleep pattern, so that a cycle is created, which may perpetuate the inflammation. The interactions between sleep and inflammation are complex. An effective immune system affects sleep, and sleep disorders affect the functioning of the immune system. Furthermore, changes in the biological clock and sleep deprivation have been directly shown to worsen ulcerative colitis in laboratory animals. In people with sleep disorders, high levels of inflammation were found. However, it is difficult to dissect the cause and effect for these associations, given their complex interactions. Therefore we are planning to conduct a prospective study to assess variety of factors that might be associated with the activity of IBD.

NCT ID: NCT04904224 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Diagnosis of Inflammatory Bowel Disease by Examining the Entire Bowel by Pan-intestinal Capsule Endoscopy

PEC
Start date: March 7, 2021
Phase: N/A
Study type: Interventional

The aim of this study is to discover inflammatory changes in the gastrointestinal tract in adult patients with suspicion of a chronic inflammatory bowel disease (IBD) by examining the entire bowel, including the small intestine, by using a video capsule. The study compares the video capsule endoscopy with colonoscopy with the question of inflammation and patient satisfaction with the respective examinations. The study is aimed at participants who present to a gastroenterologist because of their complaints like persistent abdominal pain or diarrhea. An infectious genesis and celiac disease must be ruled out in advance. In addition, the determination of the fecal calprotectin (fCal) is necessary for this study. Fecal calprotectin is a stool marker for the severity of an inflammation of the gastrointestinal tract, an increased fecal calprotectin can be an initial indication for the presence of a chronic inflammatory bowel disease. As mentioned above, participants will be examined in one of two ways: either with an examination of the small and large intestines using video capsule endoscopy in one examination (i.e. ,panintestinal capsule endoscopy', PICE) or a colonoscopy is performed as the standard treatment. Which of the two methods is used will be decided by lot, electronically controlled. Colon cleansing is necessary in preparation for both examinations. The advantage of being assigned to the video capsule group is, in addition to showing the entire intestine in one examination, that no sedation is necessary for this examination. In addition to the examination, participants have to fill out a questionnaire with information about their state of affairs, their well-being and their experience with the examination. After a period of six month the participants will be contact by phone to inquire about their current state of health.

NCT ID: NCT04896684 Recruiting - Colon Cancer Clinical Trials

Chronic Intestinal Pathologies Analytical Cohort at TouLouse

CAPITOL
Start date: April 29, 2021
Phase:
Study type: Observational

In the general population, the percentage of people with at least one digestive disease is 16.7%. Among these digestive diseases, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) and patients who should benefit from digestive examinations as part of a screening oriented either by the patient's family history or following the performance of an immunological screening test ( FIT) in the stool will be studied. The aim of this project is to build a biological collection with associated clinical data for research projects.

NCT ID: NCT04896203 Recruiting - Clinical trials for Inflammatory Bowel Diseases

Hypercoagulability Study Using Haemostatic Techniques in Patients With Inflammatory Bowel Disease

EDGAR
Start date: November 18, 2020
Phase:
Study type: Observational

Descriptive study, in which the haemostatic profile of ambulatory patients with IBD will be analyzed by means of ROTEM and other techniques, such as the thrombin generation test and the study of platelet function by flow cytometry.